Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research note published on Sunday.

ALNY has been the topic of several other reports. Oppenheimer raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target on the stock in a research report on Monday, August 4th. Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. Evercore ISI boosted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Chardan Capital boosted their price target on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Finally, Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Twenty-four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $457.16.

Alnylam Pharmaceuticals Trading Up 0.6%

Shares of NASDAQ:ALNY opened at $459.66 on Friday. The company’s 50-day moving average price is $451.37 and its two-hundred day moving average price is $346.13. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $484.21. The stock has a market capitalization of $60.25 billion, a PE ratio of -186.10 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. During the same period in the previous year, the firm posted ($0.13) EPS. The company’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $4,034,094.20. Following the transaction, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the company’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the transaction, the executive vice president owned 25,231 shares in the company, valued at approximately $11,405,673.55. This trade represents a 8.82% decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock worth $44,160,261 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. SVB Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $27,000. Bessemer Group Inc. grew its stake in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 69 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $30,000. Elevation Point Wealth Partners LLC acquired a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $37,000. Finally, Hilltop National Bank acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.